Fenofibrate
CLINICAL USE
Treatment of hyperlipidaemias types IIa, IIb, III, IV and V
DOSE IN NORMAL RENAL FUNCTION
Depends on preparation
PHARMACOKINETICS
DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20–60 134 mg daily
DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs
ADMINISTRATION
Reconstition
–
Route
Oral
Rate of Administration
–
Comments
–
OTHER INFORMATION
A few studies have noted that use of second-generation fibrates in transplant recipients is hampered by frequent rises in serum creatinineAvoid use in patients with GFR< 10 mL/min due to increased risk of rhabdomyolysis